---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011984"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:44:12.862106+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroBo completes SAD Part 1 enrollment for obesity drug DA-1726; no issues, top-line data Q3 2024

## Summary
- 45 participants enrolled across 5 cohorts in SAD Part 1 of Phase 1 trial for DA-1726 (GLP1R/GCGR dual agonist).
- No significant issues; accelerated start to MAD Part 2 dosing began June 2024.
- Top-line SAD data expected Q3 2024; MAD top-line data Q1 2025.
- Pre-clinical data showed superior weight loss vs semaglutide and survodutide, comparable to tirzepatide.
- Part 3 IND update planned; first patient dosing Q3 2025, interim data mid-2026, top-line H2 2026.

## SEC filing metadata
- accession: 0001558370-24-011984
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837024011984/0001558370-24-011984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837024011984/nrbo-20240813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011984
- JSON: https://secwatch.observer/filing/0001558370-24-011984.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.